Who are metformin+ gliclazide's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): metformin + glimepiride, MET + Glibenclamide Group.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/metformin-gliclazide.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

metformin+ gliclazide — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

metformin+ gliclazide (metformin+ gliclazide) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antidiabetic combination (biguanide + sulfonylurea). Area: Diabetes.

marketed Antidiabetic combination (biguanide + sulfonylurea) Metformin: mitochondrial glycerophosphate dehydrogenase; Gliclazide: ATP-sensitive potassium channels on pancreatic beta cells Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

metformin+ gliclazide (metformin+ gliclazide) — GlaxoSmithKline. This combination reduces blood glucose by increasing insulin secretion and improving insulin sensitivity in type 2 diabetes patients.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
metformin+ gliclazide TARGET	metformin+ gliclazide	GlaxoSmithKline	marketed	Antidiabetic combination (biguanide + sulfonylurea)	Metformin: mitochondrial glycerophosphate dehydrogenase; Gliclazide: ATP-sensitive potassium channels on pancreatic beta cells
metformin + glimepiride	metformin + glimepiride	GlaxoSmithKline	marketed	Antidiabetic combination (biguanide + sulfonylurea)	Metformin: mitochondrial glycerophosphate dehydrogenase; Glimepiride: ATP-sensitive potassium channel (KATP)
MET + Glibenclamide Group	MET + Glibenclamide Group	Hospital de Clinicas de Porto Alegre	marketed	Antidiabetic combination (biguanide + sulfonylurea)	AMPK pathway (metformin); ATP-sensitive potassium channel (glibenclamide)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antidiabetic combination (biguanide + sulfonylurea) class)

GlaxoSmithKline · 2 drugs in this class
Hospital de Clinicas de Porto Alegre · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). metformin+ gliclazide — Competitive Intelligence Brief. https://druglandscape.com/ci/metformin-gliclazide. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab